Liquidia (NASDAQ:LQDA) Now Covered by HC Wainwright

HC Wainwright started coverage on shares of Liquidia (NASDAQ:LQDA) in a report published on Friday morning, MarketBeat Ratings reports. The firm issued a buy rating and a $76.00 target price on the stock.

A number of other analysts have also recently weighed in on the company. Zacks Research cut Liquidia from a “hold” rating to a “strong sell” rating in a research report on Tuesday, September 22nd. Wells Fargo & Company lifted their price objective on Liquidia from $33.00 to $40.00 and gave the company an “equal weight” rating in a report on Wednesday. Royal Bank Of Canada set a $65.00 target price on shares of Liquidia in a research note on Thursday, October 15th. Wall Street Zen downgraded shares of Liquidia from a “buy” rating to a “hold” rating in a research note on Saturday, October 3rd. Finally, Lifesci Capital raised shares of Liquidia from a “hold” rating to an “outperform” rating and set a $59.00 target price on the stock in a report on Wednesday, October 14th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, four have assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $75.23.

Liquidia Trading Down 1.2%

LQDA stock opened at $57.41 on Friday. Liquidia has a 1-year low of $22.31 and a 1-year high of $93.61. The firm has a market cap of $5.17 billion, a P/E ratio of 26.30, a P/E/G ratio of 1.39 and a beta of 0.40. The business’s 50 day moving average is $48.96 and its 200-day moving average is $54.75. The company has a current ratio of 1.02, a quick ratio of 2.12 and a debt-to-equity ratio of 0.63.

Liquidia (NASDAQ:LQDA) last issued its earnings results on Tuesday, November 10th. The company reported ($2.64) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.96 by ($3.60). The company had revenue of $225.30 million during the quarter, compared to analyst estimates of $214.18 million. Liquidia had a positive return on equity of 264.65% and a negative net margin of 15.15%. The company’s quarterly revenue was up 314.9% on a year-over-year basis. During the same period in the previous year, the company posted ($0.04) earnings per share. Equities analysts anticipate that Liquidia will post 0.74 earnings per share for the current fiscal year.

Insider Buying and Selling at Liquidia

In related news, insider Rajeev Saggar sold 9,218 shares of the stock in a transaction that occurred on Monday, October 12th. The stock was sold at an average price of $28.48, for a total transaction of $262,528.64. Following the sale, the insider directly owned 126,368 shares in the company, valued at $3,598,960.64. This represents a 6.80% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CAO Dana Boyle sold 1,581 shares of the firm’s stock in a transaction on Monday, October 26th. The shares were sold at an average price of $43.19, for a total value of $68,283.39. Following the sale, the chief accounting officer directly owned 164,028 shares of the company’s stock, valued at $7,084,369.32. This represents a 0.95% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 566,579 shares of company stock worth $25,746,120 over the last 90 days. Company insiders own 25.60% of the company’s stock.

Institutional Trading of Liquidia

Hedge funds and other institutional investors have recently made changes to their positions in the business. Marshall Wace LLP grew its holdings in Liquidia by 112.0% during the 3rd quarter. Marshall Wace LLP now owns 155,384 shares of the company’s stock worth $4,702,000 after acquiring an additional 82,095 shares during the last quarter. First Trust Advisors LP increased its position in Liquidia by 5.3% in the 3rd quarter. First Trust Advisors LP now owns 317,407 shares of the company’s stock valued at $9,605,000 after acquiring an additional 15,975 shares in the last quarter. USS Investment Management Ltd bought a new position in shares of Liquidia in the third quarter worth about $356,000. Public Sector Pension Investment Board raised its stake in shares of Liquidia by 90.0% in the third quarter. Public Sector Pension Investment Board now owns 458,708 shares of the company’s stock worth $13,881,000 after acquiring an additional 217,332 shares during the last quarter. Finally, Ground Swell Capital LLC acquired a new position in shares of Liquidia during the third quarter worth approximately $254,000. 64.54% of the stock is currently owned by institutional investors and hedge funds.

About Liquidia

Liquidia Corporation is a biopharmaceutical company focused on developing and commercializing treatments for pulmonary hypertension and other serious diseases. Its work includes inhaled therapies designed to deliver medicines to the lungs. The company’s marketed product, Yutrepia (treprostinil) inhalation powder, is approved in the United States for adults with pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. Liquidia also has a pipeline of investigational therapies, including other formulations of treprostinil.